Ashok Srivastava

MD, Ph.D., MBA, Chief Medical Officer

Abstract Title: Clinical Advances and Future Directions of CAR T Cell Therapy in Relapsed & Refractory Patients with Solid Tumors and Hematologic Malignancies

Biography:

Dr. Ashok Srivastava is a globally recognized oncologist, hematologist, and biopharmaceutical executive with deep expertise in cancer therapeutics, cellular immunotherapy, and global oncology drug development. He currently serves as Chief Medical Officer of AyurDatta Solutions. With more than 15 years of leadership across the U.S., Europe, and Japan, Dr. Srivastava has directed clinical strategy and medical governance for complex Phase I–IV oncology programs, including multinational Phase III trials in solid tumors and hematologic malignancies. He supported 21 INDs, 7 NDAs, and 3 BLAs contributing to multiple global approvals and commercial launches.

Research Interest: